Benzinga | Jan 6, 2022 07:05AM EST

Freeline Announces FDA Clearance Of Investigational New Drug Application For FLT201 For Gaucher Disease Type 1

FLT201 is the first AAV gene therapy program to enter the clinic for GaucherdiseaseType 1



FLT201 Phase 1/2 trial for Gaucher disease Type 1 on track for patient dosing in the first half of 2022